Eli Lilly announced the selection of Goochland County, Virginia, as the site for a new $5 billion active pharmaceutical ingredient (API) manufacturing facility, the first dedicated fully integrated site supporting their bioconjugate and monoclonal antibody pipeline. The facility will bolster domestic manufacturing capacity for cancer and autoimmune disease therapies, including antibody-drug conjugates. This move is part of Lilly's broader $50 billion US investment commitment to expand manufacturing and supply chain resilience.